Flavia Borellini
Director/Board Member at REVOLUTION MEDICINES, INC.
Net worth: 375 381 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Goldsmith | M | 62 | 10 years | |
| Iain Dukes | M | 65 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | 7 years |
| Gottlieb A. Keller | M | 70 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | 40 years |
| Ivor Royston | M | 79 | 17 years | |
| Jane Chung | F | 53 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 5 years |
| Roger Pomerantz | M | 67 | 4 years | |
| Göran Forsberg | M | 61 | 10 years | |
| Thoas Michael Fioretos | M | 66 | 15 years | |
| Jeff Cislini | M | 49 | 4 years | |
| Melody Burcar | F | 41 | 2 years | |
| Mark Rothera | M | 61 | 2 years | |
| Wayne P. Rothbaum | M | 56 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | 4 years |
| Peg Horn | M | 61 | - | |
| Michel Demaré | M | 67 | 5 years | |
| Barry Simon | M | 59 | 3 years | |
| Elizabeth Anderson | F | 66 | 9 years | |
| Thomas Darcy | M | 74 | 3 years | |
| Thilo Schroeder | M | 42 | 6 years | |
| Lorence Kim | M | 49 | 2 years | |
| Sushil Patel | M | 52 | 2 years | |
| Karin Leandersson | F | 52 | 8 years | |
| Jack Anders | M | 47 | 6 years | |
| Jane Barlow | M | 63 | 3 years | |
| Patricia Delaite | M | 61 | 7 years | |
| Shu Kam Mok | M | 63 | 5 years | |
| Xiao Lin Wang | M | 53 | 6 years | |
| Stephen Rubino | M | 65 | 3 years | |
| Barbara Weber | M | 67 | 6 years | |
| Jesse Seton McGreivy | M | 54 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | - |
| Anders Martin-Löf | M | 53 | 6 years | |
| Ashleigh Barreto | F | - | 3 years | |
| Gunnar Magnus Modee Persson | M | 64 | 8 years | |
| Sam Murphy | M | 47 | 5 years | |
| Damian Marron | M | 62 | 3 years | |
| Magnus Nilsson | M | 68 | 3 years | |
| Alexis Borisy | M | 52 | 10 years | |
| Sandra Horning | M | 75 | 1 years | |
| Patric Nelson | M | - | 3 years | |
| Ayman El-Guindy | M | - | 3 years | |
| Donald Strickland | M | - | - | |
| Linnet Zia | F | - | 5 years | |
| Biljana Nadjsombati | F | - | 3 years | |
| Cindy Hoots | F | 56 | 4 years | |
| Daniel Simon | M | - | 2 years | |
| Kara Lassen | M | 45 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | 7 years |
| Patrik Renblad | M | 54 | 1 years | |
| Darrel Cohen | M | 59 | 1 years | |
| Wally Reiher | M | - | 9 years | |
| Steven Pemberton | M | - |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | - |
| Cheryl A. Madsen | F | - | - | |
| Frank Lee | M | 56 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | - |
| David Liberg | M | 55 | 9 years | |
| Wei Lin | M | 63 | 1 years | |
| Lars Thorsson | M | 63 | 9 years | |
| Dominique Tersago | M | 62 | 2 years | |
| Stewart M. Brown | M | - | 2 years | |
| Maria Fardis | M | 56 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | - |
| Nedjad Losic | M | 54 | 3 years | |
| Liselotte Larsson | M | 61 | 10 years | |
| Severin Schwan | M | 57 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | 16 years |
| Luan M. Wilfong | F | - | - | |
| Steve Kelsey | M | 63 | 7 years | |
| Roger Ulrich | M | - |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | - |
| Alan Hippe | M | 57 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | - |
| Shishir Gadam | M | 56 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Chevallard | M | 44 | 5 years | |
| David J. Scott | M | 71 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | - |
| Gur Roshwalb | M | 55 | 1 years | |
| Vincent A. Miller | M | 62 | 5 years | |
| Shriti Vadera | F | 62 | 7 years | |
| Pablo Cagnoni | M | 60 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| José Baselga | M | 65 | 2 years | |
| Shelly Vandertie | F | - | - | |
| Joseph Peter | M | 61 | - | |
| Francisco Salva | M | 53 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | 4 years |
| Neil Exter | M | 65 | 3 years | |
| Peter Svennilson | M | 62 | 1 years | |
| Eric Schmidt | M | 55 | 3 years | |
| Thomas Wiggans | M | 72 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 8 years |
| Rudolph Markham | M | 78 | 11 years | |
| William Ringo | M | 78 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
| Magnus Åke Lundberg | M | 68 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 13 years |
| Nicole Onetto | M | 71 | 2 years | |
| Wendell Wierenga | M | 76 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 17 years |
| Paul Goddard | M | 74 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 16 years |
| Antonio J. Grillo-López | M | 84 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 11 years |
| Michael Huang | M | 50 | 3 years | |
| Tausif Butt | M | 57 | 2 years | |
| Britton A. Russell | M | 35 | 1 years | |
| Henry Cremisi | M | 66 | 3 years | |
| Jim Kastenmayer | M | 52 | 7 years | |
| JoAnn Suzich | M | 68 | 1 years | |
| Jean-Charles Soria | M | 53 | 2 years | |
| Fiona Cicconi | F | 58 | 6 years | |
| Sean Bohen | M | 57 | 4 years | |
| David Wheadon | M | 66 | 5 years | |
| Kevin J. Horgan | M | 64 | 3 years | |
| Robin LaChapelle | F | 51 | 4 years | |
| Stephen Hill | M | 53 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 58 | 58.59% |
| United Kingdom | 19 | 19.19% |
| Sweden | 14 | 14.14% |
| Switzerland | 7 | 7.07% |
| Netherlands | 2 | 2.02% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Flavia Borellini
- Personal Network
